Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Peregrine Capital Management LLC

Peregrine Capital Management LLC grew its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 21.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 87,187 shares of the company's stock after acquiring an additional 15,258 shares during the quarter. Peregrine Capital Management LLC owned about 0.18% of Axsome Therapeutics worth $7,377,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock valued at $156,000 after buying an additional 318 shares during the last quarter. WCM Investment Management LLC increased its stake in Axsome Therapeutics by 0.3% during the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company's stock valued at $10,191,000 after purchasing an additional 347 shares in the last quarter. KBC Group NV grew its holdings in shares of Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock valued at $113,000 after buying an additional 385 shares during the last quarter. US Bancorp DE grew its holdings in shares of Axsome Therapeutics by 0.3% during the third quarter. US Bancorp DE now owns 133,126 shares of the company's stock valued at $11,964,000 after buying an additional 421 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in shares of Axsome Therapeutics by 4.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 19,808 shares of the company's stock valued at $1,780,000 after buying an additional 754 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 22.40% of the company's stock.

Analyst Ratings Changes

AXSM has been the subject of a number of recent research reports. Royal Bank of Canada lifted their price objective on Axsome Therapeutics from $143.00 to $192.00 and gave the company an "outperform" rating in a research note on Wednesday. Truist Financial lifted their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday. StockNews.com upgraded Axsome Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. HC Wainwright upped their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, William Blair restated an "outperform" rating on shares of Axsome Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $155.47.

Axsome Therapeutics Stock Up 6.7 %

Shares of Axsome Therapeutics stock traded up $8.65 on Friday, reaching $137.75. 1,539,189 shares of the company were exchanged, compared to its average volume of 1,103,887. The stock's 50 day moving average price is $100.34 and its 200-day moving average price is $94.46. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.37. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13. The company has a market cap of $6.72 billion, a P/E ratio of -23.00 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The company had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. As a group, equities analysts forecast that Axsome Therapeutics, Inc. will post -2.26 EPS for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.